Hurley, MJ;
Deacon, RMJ;
Chan, AWE;
Baker, D;
Selwood, DL;
Cogram, P;
(2022)
Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice.
Brain
, 145
(1)
pp. 76-82.
10.1093/brain/awab246.
Preview |
Text
Hurley_VSN16R_brain.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Fragile X Syndrome is the most common inherited intellectual disability and mono-genetic cause of autism spectrum disorder. It is a neurodevelopmental condition occurring due to a CGG trinucleotide expansion in the FMR1 gene. Polymorphisms and variants in large-conductance calcium-activated potassium channels are increasingly linked to intellectual disability and loss of FMR protein caused reduced large-conductance calcium-activated potassium channel activity leading to abnormalities in synapse function. Using the cannabinoid-like large-conductance calcium-activated potassium channel activator VSN16R we rescued behavioural deficits such as repetitive behaviour, hippocampal dependent tests of daily living, hyperactivity and memory in a mouse model of fragile X syndrome. VSN16R has been shown to be safe in a phase 1 study in healthy volunteers and in a phase 2 study in people with Multiple Sclerosis with high oral bioavailability and no serious adverse effects reported. VSN16R could therefore be directly utilised in a fragile X syndrome clinical study. Moreover, VSN16R showed no evidence of tolerance, which strongly suggests that chronic VSN16R may have great therapeutic value for fragile X syndrome and autism spectrum disorder. This study provides new insight into the pathophysiology of fragile X syndrome and identifies a new pathway for drug intervention for this debilitating disorder.
Archive Staff Only
 |
View Item |
